GOLDSMITH MARK A sold $16.7M of RVMD
GOLDSMITH MARK A (See Remarks) sold 80,000 shares of Revolution Medicines, Inc. (RVMD) at an average of $209.20 ($207.23–$212.08, $16.74M total) across 6 trades on 2026-08-21 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The sale reduces insider ownership, which may be interpreted as a bearish signal by the market.
Market read
First public disclosure of a sizable insider sell; traders may adjust positions accordingly.
What to watch
The 10b5‑1 plan was pre‑arranged, possibly unrelated to current fundamentals.
Background
SEC Form 4 filing discloses insider transactions; such filings are primary sources of material information.
Ticker impact
Officer/director sold 80,000 shares for $16.7M via a 10b5‑1 plan, reducing his stake to 267,330 shares.
Potential short‑term downward pressure on RVMD stock.
Large $16.7M sale by a senior insider under a pre‑arranged plan suggests possible concerns, but no immediate catalyst beyond the filing.
Market effects
May weigh on biotech sector sentiment as insider sales are monitored closely.
Limited to U.S. markets where RVMD trades.
Low global impact; primarily relevant to RVMD investors.
Counterpoint
Insider could be diversifying portfolio; sale does not necessarily indicate company weakness.
Key entities
- CompanyRevolution Medicines, Inc.
Biotech firm developing oncology therapies, ticker RVMD.
- IndividualMark A. Goldsmith
Officer and director of RVMD who executed the sale.
